Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T13:37:15.938Z.
Calculation as of: 2026-10-06T13:37:15.938Z.
Quote observation: 2026-10-06T13:34:58.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 934548bd97ab8c390298f716fcf622fc2d1107cfab085c47b2b47650fd31fbc6
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$711.27M
EV/Sales Ratio
1.78x
TTM Avg
2.74x
3Y Avg
3.00x
5Y Avg
3.08x
Market Cap
$657.34M
EV/Sales Ratio
6.81x
TTM Avg
3080.33x
3Y Avg
3087.28x
5Y Avg
1898.38x
Market Cap
$729.24M
EV/Sales Ratio
211.94x
TTM Avg
133.47x
3Y Avg
94.21x
5Y Avg
94.21x
Market Cap
$721.69M
EV/Sales Ratio
N/A
TTM Avg
0.38x
3Y Avg
0.82x
5Y Avg
6.17x
Market Cap
$644.17M
EV/Sales Ratio
1.84x
TTM Avg
1.55x
3Y Avg
1.11x
5Y Avg
1.54x
Market Cap
$751.75M
EV/Sales Ratio
N/A
TTM Avg
777.64x
3Y Avg
653.12x
5Y Avg
653.12x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Helus Pharma Inc. (HELP) | $696.39M | N/A | N/A | N/A | N/A |
| Faeth Therapeutics, Inc. (FTH)vs › | $684.30M | N/A | N/A | N/A | N/A |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $711.27M | 1.78x | 2.74x | 3.00x | 3.08x |
| Annexon, Inc. (ANNX)vs › | $675.03M | N/A | N/A | N/A | N/A |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $657.34M | 6.81x | 3080.33x | 3087.28x | 1898.38x |
| Anteris Technologies Global Corp. (AVR)vs › | $729.24M | 211.94x | 133.47x | 94.21x | 94.21x |
| Achieve Life Sciences, Inc. (ACHV)vs › | $721.69M | N/A | 0.38x | 0.82x | 6.17x |
| AngioDynamics, Inc. (ANGO)vs › | $644.17M | 1.84x | 1.55x | 1.11x | 1.54x |
| Candel Therapeutics, Inc. (CADL)vs › | $751.75M | N/A | 777.64x | 653.12x | 653.12x |
| Aura Biosciences, Inc. (AURA)vs › | $639.24M | N/A | N/A | N/A | N/A |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
